Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: A systematic review of economic evidence

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 9, 2007, Pages 1369-1377

  Sun, Xin ^a,b   Qin, Wen Xia ^a,b   Li, You Ping ^a,b   Jiang, Xu Hua ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Antiviral therapy; Chronic hepatitis B; Cost effectiveness; Economic evidence

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; THYMOSIN;

ALTERNATIVE MEDICINE; ANTIVIRAL THERAPY; AUSTRALIA; CHINA; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA BASE; ECONOMIC ASPECT; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HEPATITIS B; HUMAN; METHODOLOGY; MONOTHERAPY; OUTCOME ASSESSMENT; POLAND; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITATIVE RESEARCH; REVIEW; SALVAGE THERAPY; SCREENING TEST; SPAIN; SYSTEMATIC REVIEW; TAIWAN; UNITED STATES;

EID: 34547972817     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05068.x     Document Type: Review

References (39)

1. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statement on the prevention and management of hepatitis B and C in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000 15 : 825 41.
2. Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J. Gastroenterol. Hepatol. 2000 15 : 1356 61.
3. Safeary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. J. Gastroenterol. Hepatol. 2000 15 : 396 401.
4. Locarnini SA, Newbold JE. Chronic hepatitis B: the therapeutic challenge. J. Antimicrob. Chemother. 1997 39 : 559 65.
5. Liaw YF. Management of patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2002 15 : 396 401.
6. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997 336 : 347 56.
7. Lok ASF, McMahon BJ. Chronic hepatitis B: update recommendations. Hepatology 2004 39 : 1 5.
8. Marcellin P. Advances in therapy for chronic hepatitis B. Semin. Liver Dis. 2002 22 (Suppl. 1 33 6.
9. Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment. Pharmacol. Ther. 2004 19 : 25 37.
10. Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003 18 : 239 45.
11. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999 30 : 1082 7.
12. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin a1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998 27 : 1383 7.
13. Angus PW, Hepatitis B. Weighing the costs of treatment. J. Gastroenterol. Hepatol. 2002 17 : 737 8.
14. Pwu RF, Chan KA. Cost-effectiveness analysis of interferon-therapy in the treatment of chronic hepatitis B in Taiwan. J. Formos. Med. Assoc. 2002 101 : 632 41.
15. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000 17 : 409 27.
16. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med. 1995 122 : 664 75.
17. Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia 2002 43 : 550 8.
18. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000 39 : 28 33.
19. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int. J. Technol. Assess. Health Care 2005 21 : 240 5.
20. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford : Oxford University Press, 1987.
21. Sculpher MJ, Pang FS, Manca A et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol. Assess. 2004 8 : 1 192.
22. Antonanzas F. Transferability of economic evaluation results. Pharmacoeconomics 2004 22 : 827.
23. Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ 2001 322 : 1596 8.
24. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BMG. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann. Intern. Med. 2005 142 : 821 31.
25. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J. Gastroenterol. Hepatol. 2002 17 : 153 64.
26. Orlewska E. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland. Value Health 2002 5 : 405 12.
27. Buti M, Casado MA, Calleja JL, Salmeró NJ, Aguilar J, Rueda M. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2006 23 : 409 19.
28. Sullivan SD, Veenstra DA, Chen PJ et al. Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J. Gastroenterol. Hepatol. 2006 22 : 1494 9.
29. He H, Yu GL. Comparing the effect and economic effectiveness of interferon alfa-1b and lamivudine in treating chronic hepatitis B. Guangdong Pharm. J. 2002 12 : 52 3.
30. Wei HY. Application of cost-effectiveness analysis in three therapeutic schemes for chronic hepatitis B. China Pharm. J. 2000 11 : 265.
31. Yang ZH, Chen YH. Cost-effectiveness of three therapeutic strategies for chronic hepatitis B. Acad. J. Guangdong Coll. Pharm. 2001 17 : 135 6.
32. Zhang H, Wang RS, Zhang J, Kong HW, Zhu YF, Fu HB. Cost-effectiveness analysis of antiviral strategies in patients with chronic hepatitis B. Lin Chuang Hui Cui 2002 17 : 441 2.
33. Zhou XQ, Wang NS, Meng J. Pharmacoeconomic study of interferon on patients with chronic hepatitis B. J. Mathemat. Med. 2004 17 : 348 9.
34. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with Interferon-a in the treatment of chronic hepatitis B in the United States. Am. J. Manag. Care 2001 7 : 677 82.
35. Wang RL, Ye XG. A comparison of cost-effectiveness between alpha-2b and lamivudine in treating chronic hepatitis B. Evaluat. Anal. Drug Use Hosp. China 2002 2 : 26 7.
36. Wu LL, Liu CX, Ying XF. The analysis of effectiveness and cost of lamivudine in treatment of chronic hepatitis. Chin. J. New Drugs 2002 11 : 811 13.
37. Yan JZ. Cost-effectiveness analysis of interferon-alpha 1b with lamivudine. IMHGN 2004 10 : 58 9.
38. Sun X, Li YP, Zhou RL et al. Comparative effectiveness of lamivudine monotherapy for patients with chronic hepatitis B. Proceedings of ISPOR, the 2nd Asian Pacific Conference; 5-7 March 2006, Shanghai, China.
39. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 2003 337 : 1733 45.